

Mosid MT tablets are used to treat gastroesophageal reflux disease, as well as eliminate dyspeptic symptoms of the gastrointestinal tract (heartburn, nausea) associated with diseases of the gastroduodenal zone.
The active substance is mosapride (one tablet contains mosapride citrate dihydrate equivalent to 5 mg mosapride citrate).
Excipients: mannitol (E 421), anhydrous colloidal silicon dioxide, special orange powder, peppermint powder, aspartame (E 951), talc, crospovidone, magnesium stearate, yellow iron oxide (E172), red iron oxide (E 172).
The usual dose of Mosid MT is 5 mg 3 times a day before or after meals.
The tablet dissolves quickly in the mouth, if necessary, it can be washed down with water.
The maximum daily dose is 40 mg.
The course of treatment is determined by the doctor individually.
Data on the use of mosapride in pregnant women is limited, therefore, the drug can be prescribed during pregnancy only in cases where the expected benefit to the mother outweighs the potential risk to the fetus.
Mosapride passes into breast milk, so you should avoid using the drug during lactation.
The efficacy and safety of the use of mosapride in children has not been established, therefore, the drug should not be used in this category of patients.
"Mosid MT" in therapeutic doses does not affect the speed of motor reactions. In case of side effects, one should refrain from driving vehicles or working with complex mechanisms.
There is no information about an overdose of mosapride, however, an increase in the manifestations of adverse reactions is possible. There are no specific antidotes. Gastric lavage, intake of activated carbon, symptomatic treatment are recommended.
The total frequency of side effects with oral administration of the drug is not more than 7%. Adverse reactions are possible, which are listed below.
From the digestive tract: diarrhea, constipation, nausea, dry mouth, abdominal pain, vomiting.
From the nervous system: general weakness, headache, insomnia, dizziness, impaired consciousness.
From the cardiovascular system: palpitations, tachycardia.
On the part of the skin: allergic reactions, including skin rashes, urticaria.
Laboratory changes: eosinophilia, increased triglycerides, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase.
Since the Mosid MT preparation is deprived of the properties of a dopamine D2 receptor antagonist, it does not affect the central nervous system and does not cause extrapyramidal disorders.
Store in the original packaging at a temperature not exceeding 25 ° C, out of the reach of children.
Shelf life is 3 years.